Efficacy
| Best response . | Evaluable patients (n = 23) . | AITL (n = 14) . | PTCL-NOS (n = 6) . | |||
|---|---|---|---|---|---|---|
| Number . | Response rate, n (%) . | Number . | Response rate, n (%) . | Number . | Response rate, n (%) . | |
| ORR | 15 | 65.2 | 11 | 78.6 | 3 | 50 |
| CR | 6 | 26.1 | 5 | 35.7 | 1 | 16.7 |
| PR | 9 | 39.1 | 6 | 42.9 | 2 | 33.3 |
| SD | 2 | 8.7 | 1 | 7.1 | 1 | 16.7 |
| PD | 6 | 26.1 | 2 | 14.3 | 2 | 33.3 |
| Median Follow-up | 15.7 mo | |||||
| Median time to BR | 86 d | |||||
| 2-y PFS (n = 23) (%) | 31.5 (95% CI, 16.1-61.5) | |||||
| 2-y OS (n = 23) (%) | 49.5 (95% CI, 31.6-77.8) | |||||
| Best response . | Evaluable patients (n = 23) . | AITL (n = 14) . | PTCL-NOS (n = 6) . | |||
|---|---|---|---|---|---|---|
| Number . | Response rate, n (%) . | Number . | Response rate, n (%) . | Number . | Response rate, n (%) . | |
| ORR | 15 | 65.2 | 11 | 78.6 | 3 | 50 |
| CR | 6 | 26.1 | 5 | 35.7 | 1 | 16.7 |
| PR | 9 | 39.1 | 6 | 42.9 | 2 | 33.3 |
| SD | 2 | 8.7 | 1 | 7.1 | 1 | 16.7 |
| PD | 6 | 26.1 | 2 | 14.3 | 2 | 33.3 |
| Median Follow-up | 15.7 mo | |||||
| Median time to BR | 86 d | |||||
| 2-y PFS (n = 23) (%) | 31.5 (95% CI, 16.1-61.5) | |||||
| 2-y OS (n = 23) (%) | 49.5 (95% CI, 31.6-77.8) | |||||
BR, best response; PD, progression of disease; PR, partial response; SD, stable disease.